How much conservatism is baked into the new guidance, particularly concerning external factors like oil prices and geopolitical events?

The estimated impact from the Middle East conflict is $70 million for FY26, assuming diesel prices around $5 and raw material costs from two weeks prior. Tariff rates are assumed not to change for the rest of the year, with any future changes impacting 2027. “On the Middle East side, just to give you a number, we have a $70 million of estimated expected impact for 2026 in our overall guide.”

Are operational investments increasing further, and what are examples of these investments? Are they becoming part of the run rate?

Operational investments are not new but have increased due to faster-than-anticipated demand growth. Examples include staffing, technology, and scaling efforts, adding new distribution centers in Texas, California, and the Midwest. These create near-term inefficiencies but are expected to drive long-term efficiency and savings. The labor burden is added in advance of revenue realization. “We're also expanding our network capacity by adding new distribution centers. Jim talked about it previously, we were adding a DC in Texas, righting in D.C. in California. We're also talking biting a couple more D.C., in the Midwest to help support this current growth.”

How do the internal and external pressures impacting EBITDA guidance split between transitory and permanent for 2027 and beyond?

Roughly half of the cost impact is transitory (Middle East, Tracy fire impact subsiding over time) and half is permanent (operational investments, quality investments). Product-related quality costs are more temporary. Retail softness is short-term permanent but efforts are underway to improve it. Cost savings initiatives are ongoing to mitigate the permanent burden. “So if you think about, we roughly have estimated about half of the cost or the impact of margin is transitory and about half of it is really permanent will roll into our base overall.”

MDLN

Medline (MDLN) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

Medline Q2 FY26 — Strong Top-Line Growth Offset by Margin Headwinds and Strategic Investments

Medline delivered robust top-line growth in Q2 FY26, driven by strong organic performance and new customer acquisitions, leading to a second upward revision of its full-year sales outlook. However, the company faces significant margin pressures from the Tracy fire, increased operational and quality investments, and retail channel softness, resulting in a lowered adjusted EBITDA guidance. Management emphasizes strategic investments for long-term growth and competitive positioning, while actively pursuing cost savings and evaluating future pricing actions to restore margin profiles.

Highlights

Net sales increased 12% year-over-year to $7.7 billion, driven by organic growth.
Organic sales guidance for FY26 raised for the second time to 9%-10% from 8.5%-9.5%.
New customer signings reached over $650 million in the first half, representing over 65% of the $1 billion annual goal.
Adjusted EBITDA increased 13% year-over-year to $1.1 billion, including a $243 million net IEEPA tariff refund benefit.
Net leverage reduced to 2.9x, achieving the long-term goal of less than 3x.

Concerns

Full year adjusted EBITDA guidance lowered to $3.3 billion-$3.4 billion from $3.5 billion-$3.6 billion.
Tracy distribution center fire resulted in $336 million in net income reduction (excluded from adjusted EBITDA), with an additional $50 million-$100 million in costs expected in H2 2026.
Retail channel softness impacted Front Line Care and U.S. non-acute sales and margins, expected to remain a headwind.
Increased operational investments and quality remediation efforts are creating near-term inefficiencies and margin pressure.
Middle East conflict contributing to higher-than-expected inflationary pressure, estimated at $70 million for FY26.

Guidance & targets

Category	Target	Timeline	Confidence
Full year organic sales growth	9% to 10% high materiality	FY26	High
Full year adjusted EBITDA	$3.3 billion to $3.4 billion high materiality	FY26	Medium
Full year 2026 net tariff impacts	approximately $350 million medium materiality	FY26	High
Full year tax distributions	$250 million to $300 million low materiality	FY26	High
Full year CapEx	$500 million to $600 million medium materiality	FY26	High
Adjusted EBITDA growth rate	at or above the rate of sales growth high materiality	Long-term	Medium

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Medline Brands Customer repayments tied to IEEPA tariff refunds reduced growth by approximately 3 percentage points. First half net sales were $7 billion, up 6% YoY.	$3.5 billion	7%	—	—
Surgical Solutions Customer repayments tied to IEEPA tariff refunds reduced growth by approximately 3 percentage points. Strong growth driven by surgical kitting. First half net sales were $3.2 billion, up 8% YoY.	$1.6 billion	9%	—	—
Front Line Care Customer repayments tied to IEEPA tariff refunds reduced growth by approximately 3 percentage points. Strong demand in exam gloves and personal care, partially offset by unplanned retail channel softness. First half net sales were $3.3 billion, up 5% YoY.	$1.7 billion	4%	—	—
Lab and Diagnostics Driven by new customer implementations and existing customer demand, including strong core acute care lab growth from multichannel prime vendor agreements. First half net sales were $541 million, up 6% YoY.	$248 million	12%	—	—
Supply Chain Solutions Supported by new customer implementations and growth with existing customers, expanding opportunity for Medline brand conversion. First half net sales were $8 billion, up 16% YoY. Margin impacted by year 1 rebates and operational investments.	$4.1 billion	16%	—	4.9% adjusted EBITDA margin
U.S. Acute Care Driven by new Prime Vendor customers and existing customer growth. Customer repayments tied to IEEPA tariff refunds reduced growth by approximately 1 percentage point. First half net sales were $10.5 billion, up 13% YoY.	$5.4 billion	15%	—	—
U.S. Non-Acute Care Growth primarily driven by existing customers and new customer signings in physician office and post-acute channels, partially offset by retail softness. Customer repayments tied to IEEPA tariff refunds reduced growth by approximately 2 percentage points. First half net sales were $3.5 billion, up 5% YoY.	$1.7 billion	4%	—	—
International Driven by volume growth in Canada and Europe. First half net sales were $1 billion, up 10% YoY.	$533 million	9%	—	—

Deals & partnerships

Allina Health Expanded prime vendor agreement

Expanded presence in the Upper Midwest, covering acute care and physician office settings. Went live about 3 weeks prior to the call.

Risks & headwinds

Tracy distribution center fire costs Q2 FY26 and H2 FY26

$336 million net income reduction in Q2 FY26; additional $50 million-$100 million expected in H2 FY26

Mitigation:Leveraging existing inventory and distribution network, securing 1.6 million sq ft of new DC space, expected insurance recoveries.

Middle East conflict inflationary pressure FY26

Estimated $70 million impact for FY26 (fuel, product costs)

Mitigation:Absorbing costs to maintain customer relationships and gain share, leveraging cross-sourcing relationships, monitoring situation.

Increased operational investments Near-term

Contributing to 75% of incremental earnings impact (internal factors)

Mitigation:Investing in staffing, technology, and scaling efforts to meet demand; adding new distribution centers to drive future efficiencies.

Quality remediation efforts Near-term

Contributing to 75% of incremental earnings impact (internal factors); products taking longer to reintroduce to market (e.g., CHG lives)

Mitigation:Enhancing quality organization, investing in manufacturing network, proactive engagement with FDA on global quality action plan.

Retail channel softness Balance of the year

Impacting Front Line Care and U.S. non-acute sales and margins; contributing to 75% of incremental earnings impact (internal factors)

Mitigation:Realigning sales organization around retail customers and their specific needs, working to earn back lost business.

Tariff rate changes FY26 and FY27

Full year 2026 net tariff impacts estimated at $350 million (down from $490 million); any further changes immaterial for 2026 but affect 2027

Mitigation:Leveraging significant inventory on hand to mitigate immediate impact, monitoring fluid situation.

What to watch in Q3 FY26

Retail channel performance

next quarter

Current Softness impacting Front Line Care and U.S. non-acute sales

Target Improvement in sales and margins, successful regaining of lost business

Why it matters

Retail softness disproportionately impacts Medline brand profitability and is a key internal headwind.

While we are taking steps to improve retail, we expect it to remain a headwind for the balance of the year.

Find out whether MDLN delivers this. Inve re-checks your case every morning.

Q&A highlights

Is overspending on growth part of the strategy for share gains, and what market conditions are needed to return to EBITDA growth above revenue growth?

Management confirmed that investing ahead of growth is a long-standing strategy, citing investments in distribution centers, manufacturing, and sales teams. They are happy with underlying performance and expect continued strength. Returning to EBITDA leverage requires continued execution on operational investments, quality remediation, and new customer signings.

“If you think about our business, we've been intentional for many, many years of investing in our business for growth ahead of the growth.”

asked by Michael Cherny · answered by Michael Drazin

2 min read 6 chapters

Detailed narrative

Strong Commercial Execution and Customer Signings

Medline achieved significant commercial momentum in Q2 FY26, securing over $650 million in new customer signings in the first half, tracking ahead of its $1 billion annual goal. These wins span across various channels including acute care, physician office, lab, skilled nursing, senior living, home health, and hospice, demonstrating the company's ability to gain market share.

A notable win was an expanded prime vendor agreement with Allina Health in the Upper Midwest, covering acute care and physician office settings.

Response to Tracy Distribution Center Fire

The company demonstrated resilience in responding to the mid-June fire at its Tracy, California distribution center. Leveraging its broad distribution network and inventory, Medline minimized customer disruption. Within a month, 1.6 million square feet across two new distribution centers were secured, expanding the Northern California footprint by 45%.

The new Tracy DC is expected to serve customers in Q4, and a new stocking facility in January 2027, reinforcing supply chain resiliency.

Strategic Infrastructure Investments

Beyond the Tracy fire recovery, Medline announced plans for a new 1 million square foot distribution center in Southern California, aiming to reach nearly 5 million square feet across California by mid-2027. These investments in new facilities and automation technologies are designed to enhance supply chain flexibility, redundancy, and capacity, supporting future growth and anticipating customer demand.

The company views these as crucial for maintaining its position as a vertically integrated manufacturer and distributor.

Quality Remediation and Operational Investments

Medline is undertaking significant remediation activities to strengthen its quality organization and manufacturing processes, proactively engaging with the FDA on a global quality action plan. These investments include people, processes, and technology, accelerating initiatives to support growth. The company also modified its complaint review process, expecting an increase in medical device reporting (MDR) submissions in the second half, reflecting enhanced vigilance.

Retail Channel Softness and Strategic Realignment

The retail business, representing less than 2% of overall sales but almost entirely Medline brand, experienced unplanned softness, impacting Front Line Care and U.S. non-acute sales and margins. This was attributed to the loss of a portion of a customer due to a lack of understanding of customer needs.

In response, Medline has realigned its sales organization to better support retail customers and improve competitiveness, aiming to regain lost business despite the channel's inherent volatility.

Tariff Impacts and Pricing Strategy

The company recorded a net IEEPA tariff refund benefit of $243 million in Q2, which was excluded from adjusted EBITDA guidance to show underlying performance. Full-year net tariff impacts are now estimated at $350 million, down from $490 million previously.

Medline has chosen to absorb inflationary pressures from the Middle East conflict and other costs rather than broadly pass them to customers, aiming to maintain long-term relationships and gain market share, while reserving pricing as a future option once cost impacts stabilize.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.